Table 2.
Demographic, laboratory tests and tumor-related characteristics of study groups.
| Characteristic | Category | HCC groupa (n = 51) | CLDb (n = 21) | HDc (n = 31) | p value |
|---|---|---|---|---|---|
| Gender | Male n (%) | 49 (96.1%) | 20 (95.2%) | 28 (90.3%) | > 0.05 |
| Female n (%) | 2 (3.9%) | 1 (4.8%) | 3 (9.7%) | ||
| Age (years) | < 50 | 10 (19.6%) | 15 (71.4%) | 16 (51.6%) | < 0.05 |
| 50–59 | 12 (23.5%) | 1 (4.8%) | 7 (22.6%) | ||
| 60–69 | 16 (31.4%) | 5 (23.8%) | 4 (12.9%) | ||
| > 70 | 13 (25.5%) | 0 (0%) | 4 (12.9%) | ||
| Median (IQR) | 62 (50.3–69.8) | 45 (41.0–55. 3) | 49.0 (37.3–60.5) |
p(a,b) = 0.00* p(a,c) = 0.01* |
|
| PLT | Median (IQR) | 163.0 (115.0–192.0) | 173.0 (127.0–210. 5) | – | – |
| Prothrombin % | Median (IQR) | 82 (75.3–88.8) | – | – | – |
| INR | Median (IQR) | 1.15 (1.08–1.22) | – | – | – |
| Albumin | Median (IQR) | 38.0 (36.0–40.85) | – | – | – |
| Bilirubin total | Median (IQR) | 15.5 (11.96–20.98) | 13.5 (10.7–17.5) | – | – |
| PIVKA II (n = 17) | Median (IQR) | 580.0 (86.01–4328.04) | – | – | – |
| AFP | Median (IQR) | 35.13 (9.47–1426.92) | 3.44 (2.35–4.34) | – | – |
| AST | Median (IQR) | 49.76 (35.3–98.5) | 29.7 (26.0–53.9) | 25.96 (22.9–31.0) |
pa,c < 0.05 pb,c < 0.05 |
| ALT | Median (IQR) | 43.44 (33.0–62.7) | 36.53 (25.2–47.1) | 22.49 (17.5–25.5) |
Pa,c < 0.05 Pb,c < 0.05 |
| Cirrhosis | Yes | 22 (43.1%) | 6 (28.6%) | 0 (0%) | – |
| No | 29 (56.9%) | 15 (71.4%) | 31 (100%) | – | |
| Risk factor | HBV | 42 (82.4%) | 21 (100.0%) | 0 | – |
| HCV | 7 (13.7%) | 0 (0%) | 0 | – | |
| Alcohol-related | 11 (21.6%) | – | 0 | – | |
| Number of tumors | Single n (%) | 28 (54.9%) | – | ||
| Two n (%) | 11 (21.6%) | – | |||
| Three n (%) | 1 (2.0%) | – | |||
| More than Three n (%) | 11 (21.6%) | – | |||
| Greatest diameter (mm) | Median (IQR) | 42 (28.2–74.5) | – | ||
| Tumor location | Right lobe n (%) | 27 (52.9%) | – | ||
| Left lobe n (%) | 9 (17.7%) | – | |||
| Both n (%) | 15 (29.4%) | – | |||
| Vascular invasion | Yes | 12 (23.5%) | – | ||
| No | 39 (76.5%) | – | |||
| Metastatic Lymph Node | Yes | 3 (5.9%) | – | ||
| No | 48 (94.1%) | – | |||
| Extrahepatic spread | Yes | 6 (11.8%) | – | ||
| No | 45 (88.2%) | – | |||
| BCLC stage | 0,A | 28 (54.9%) | – | – | |
| B | 8 (15.7%) | – | – | ||
| C | 13 (25.5%) | – | – | ||
| D | 2 (3.9%) | – | – |
Significant values are in [bold].